Syndax Pharmaceuticals at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Syndax Pharmaceuticals brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 3539. Its program centres on acute myeloid leukemia and the career paths open to trainees. It supports a debate on frontline AML treatment and presents a session on relapsed NPM1-mutated AML, plus research on revumenib dosing.
| Organization | ASH 2026 Attendance |
|---|---|
Syndax Pharmaceuticals Waltham, MA | |
Commercial-stage biotech with a menin inhibitor for relapsed or refractory acute leukemia and a CSF-1 receptor antibody for chronic GVHD. | Booth Exhibiting at Booth 3539 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Session Sun Dec 13 11:15am–12:15pm Poster Sun Dec 13 6:00pm–8:00pm Talk Mon Dec 14 8:00am–9:00am Session |
Find decision makers at Syndax Pharmaceuticals
Tell us what you sell and we’ll find the people at Syndax Pharmaceuticals most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction